AbCheck is now a part of Ampersand Biomedicines
View Press Release
ABCheck
ABCheck
ABCheck
ABCheck

Meeting Your Needs in
Cutting-edge Antibody Discovery
and Development
ABCheck

AbCheck is now a part of Ampersand Biomedicines
View Press Release
ABCheck

Meeting Your Needs in
Antibody Discovery
and Development

AbCheck discovers and optimizes human therapeutic antibodies with one of the industry’s most versatile technology platforms. Tailored to specific needs and desired Target Product Profiles, AbCheck leverages both cutting-edge (e.g., microfluidics, rabbit mass humanization) and state-of-the-art (e.g., phage/yeast display libraries) technologies to provide high quality leads. The company has proven its capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly-owned subsidiary of Ampersand Biomedicines, a Flagship Pioneering Company.

Our Approach

Applications

Our technologies

Unique Technology Solutions and
State-of-the-Art Antibody Discovery Technologies

Microfluidics

Technologies


Rabbit Mass
Humanization

Technologies

Single Copy
Integration Site
Technology

Technologies

State-of -the-Art
Antibody Discovery
Technologies

Technologies
We are trusted leaders
in antibody discovery
and development
Partner with us

Our Services

Antibody
Discovery

Services

Antibody
Optimization

Services

Our Unique Platforms

Proprietary
Libraries

Technologies

Rabbit Mass
Humanization

Technologies

AbSieve®
Antibody
Selection

Technologies

AbAccel®
Antibody
Optimization

Technologies